160 related articles for article (PubMed ID: 12417606)
1. Report of the fifteenth international symposium of the foundation for promotion of cancer research: new horizons in the diagnosis and treatment of hematological malignancies based on molecular genetic features.
Multani PS; Tobinai K; Kakizoe T; Armitage JO; Ohno R; Sugimura T
Jpn J Clin Oncol; 2002 Sep; 32(9):371-85. PubMed ID: 12417606
[TBL] [Abstract][Full Text] [Related]
2. [Advances in the target therapy of hematological malignancies].
Niu T; Liu T
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):642-6. PubMed ID: 25286692
[TBL] [Abstract][Full Text] [Related]
3. Exploring Big Data in Hematological Malignancies: Challenges and Opportunities.
Westin GF; Dias AL; Go RS
Curr Hematol Malig Rep; 2016 Aug; 11(4):271-9. PubMed ID: 27177742
[TBL] [Abstract][Full Text] [Related]
4. Wilms' Tumor Gene 1 (WT1) Peptide Vaccine Therapy for Hematological Malignancies: From CTL Epitope Identification to Recent Progress in Clinical Studies Including a Cure-Oriented Strategy.
Oka Y; Tsuboi A; Nakata J; Nishida S; Hosen N; Kumanogoh A; Oji Y; Sugiyama H
Oncol Res Treat; 2017; 40(11):682-690. PubMed ID: 29041012
[TBL] [Abstract][Full Text] [Related]
5. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
Shor B; Gerber HP; Sapra P
Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
[TBL] [Abstract][Full Text] [Related]
6. Expression patterns of costimulatory molecules on cells derived from human hematological malignancies.
Zheng Z; Takahashi M; Aoki S; Toba K; Liu A; Osman Y; Takahashi H; Tsukada N; Suzuki N; Nikkuni K; Furukawa T; Koike T; Aizawa Y
J Exp Clin Cancer Res; 1998 Sep; 17(3):251-8. PubMed ID: 9894758
[TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity conditioning in allogeneic stem cell transplantation for hematological malignancies: a historical perspective.
Cremer B; Sandmaier BM; Bethge W; Lange T; Goede V; Holtick U; Hallek M; Hübel K
Onkologie; 2011; 34(12):710-5. PubMed ID: 22156452
[TBL] [Abstract][Full Text] [Related]
8. A novel therapeutic approach for hematological malignancies based on cellular differentiation and apoptosis.
Kizaki M; Nakazato T; Ito K; Kawamura C; Miyakawa Y; Ikeda Y
Int J Hematol; 2002 Aug; 76 Suppl 1():250-2. PubMed ID: 12430859
[TBL] [Abstract][Full Text] [Related]
9. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies.
Countouriotis A; Moore TB; Sakamoto KM
Stem Cells; 2002; 20(3):215-29. PubMed ID: 12004080
[TBL] [Abstract][Full Text] [Related]
10. CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies.
Shanehbandi D; Majidi J; Kazemi T; Baradaran B; Aghebati-Maleki L
Curr Cancer Drug Targets; 2017; 17(5):423-444. PubMed ID: 28067179
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
12. The immune system as a foundation for immunologic therapy and hematologic malignancies: a historical perspective.
Baron F; Storb R
Best Pract Res Clin Haematol; 2006; 19(4):637-53. PubMed ID: 16997174
[TBL] [Abstract][Full Text] [Related]
13. Low- versus high-dose radioimmunotherapy with humanized anti-CD22 or chimeric anti-CD20 antibodies in a broad spectrum of B cell-associated malignancies.
Behr TM; Wörmann B; Gramatzki M; Riggert J; Gratz S; Béhé M; Griesinger F; Sharkey RM; Kolb HJ; Hiddemann W; Goldenberg DM; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3304s-3314s. PubMed ID: 10541379
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics of patients with hematological malignancies at gondar university hospital, North West Ethiopia.
Weldetsadik AT
Ethiop Med J; 2013 Jan; 51(1):25-31. PubMed ID: 23930488
[TBL] [Abstract][Full Text] [Related]
15. Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Abuelgasim KA; Rehan H; Alsubaie M; Al Atwi N; Al Balwi M; Alshieban S; Almughairi A
J Med Case Rep; 2018 Mar; 12(1):64. PubMed ID: 29524963
[TBL] [Abstract][Full Text] [Related]
16. Graft-versus-host and graft-versus-leukemia reactions: a summary of the Seventh International Symposium held in Garmisch-Partenkirchen, Germany, February 22nd-25th, 2006, Tolerance and Immunity, an update on lymphoid malignancies.
Munker R; Reibke R; Kolb HJ
Bone Marrow Transplant; 2006 Nov; 38(9):593-607. PubMed ID: 16980992
[TBL] [Abstract][Full Text] [Related]
17. Hematopoietic stem cell transplantation in hematologic malignancy.
Archuleta TD; Devetten MP; Armitage JO
Panminerva Med; 2004 Mar; 46(1):61-74. PubMed ID: 15238882
[TBL] [Abstract][Full Text] [Related]
18. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
Slavin S; Morecki S; Weiss L; Or R
J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
[TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling for diagnosis and therapy in acute leukaemia and other haematologic malignancies.
Bacher U; Kohlmann A; Haferlach T
Cancer Treat Rev; 2010 Dec; 36(8):637-46. PubMed ID: 20570445
[TBL] [Abstract][Full Text] [Related]
20. Clinically useful information provided by the flow cytometric immunophenotyping of hematological malignancies: current status and future directions.
Orfao A; Schmitz G; Brando B; Ruiz-Arguelles A; Basso G; Braylan R; Rothe G; Lacombe F; Lanza F; Papa S; Lucio P; San Miguel JF
Clin Chem; 1999 Oct; 45(10):1708-17. PubMed ID: 10508115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
